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Abstract: Poor inhaler technique hampers the efficacy of drug therapy in asthma and chronic 
obstructive pulmonary disease. Not only does this affect individual patient care, but it also impacts 
on the wider health care economics associated with these conditions. Treatment guidelines recom-
mend a systematic approach to drug class selection; however, standardization of inhaler selection 
is currently difficult owing to the complexity of the interaction between the inhaler device and 
the patient. Specifically, individual patient preference can influence how successful a treatment is 
overall. This article reviews inhaler devices from the patient perspective, with a particular focus 
on the dry powder inhaler HandiHaler® and Respimat® Soft Mist™ Inhaler. It discusses factors 
that influence device preference and treatment compliance and reviews tools that can aid health 
care professionals to better match inhaler devices to individual patients’ needs.
Keywords: asthma, chronic obstructive pulmonary disease, inhaler technique, Soft Mist™ 
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Introduction
Inhaled therapy remains the cornerstone of treatment for pulmonary disorders such 
as asthma and chronic obstructive pulmonary disease (COPD). It offers advantages 
over oral tablet administration, such as effective targeting of treatment to the lungs at 
a lower dose with a rapid onset of action.1–5
Despite the introduction of new pharmacological treatments and the availability 
of a range of different types of inhaler devices,1,2,5 asthma and COPD often remain 
suboptimally controlled in terms of symptom relief and reduction in exacerbation 
risk.6,7 Incorrect use of inhaler devices is common – real-world studies estimate that 
up to 94% of patients do not use their inhalers properly.6,8,9 This can lead to inadequate 
drug dosing, which, in turn, contributes to a worsening of quality of life and suboptimal 
disease control.8–11
With over 200 different drug–inhaler combinations available,2 matching patient 
characteristics and preferences to the most appropriate drug treatment and inhaler 
device remains challenging. Clinical respiratory practice in the majority of patients is to 
first select the class of medication, followed by the specific agent, and then the inhaler 
device itself. However, the importance of inhaler selection as part of the treatment deci-
sion is becoming increasingly recognized,2,9,12–14 and this article proposes that careful 
consideration of inhaler selection warrants greater priority among prescribers.
This review examines the key considerations for selecting devices most suited 
to patients’ needs; it also discusses the importance of correct inhaler technique for 
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optimizing treatment outcomes and evaluates patients’ per-
spectives and preferences when switched from a dry powder 
inhaler (DPI) to the Respimat® Soft Mist™ Inhaler (SMI; 
Boehringer Ingelheim International GmbH, Ingelheim am 
Rhein, Germany).
The case for monitoring inhaler 
suitability
Treatment guidelines emphasize that good symptom control 
with inhaled maintenance drugs is fundamental to the man-
agement of asthma and COPD.3,4 Nevertheless, guidelines 
have lacked clarity on specific guidance regarding appropriate 
inhaler selection for achieving optimum symptom control.2,14 
It is encouraging, however, to see that the latest Global Initia-
tive for Asthma and Global Initiative for Chronic Obstructive 
Lung Disease strategy documents both state the importance 
of inhaler device selection in day-to-day practice.3,4
It is well established that poor inhalation technique 
can severely impact the clinical efficacy of medications, 
resulting in impaired disease control, worsening quality of 
life, increased exacerbation and mortality risk, increased 
hospitalizations (Figure 1), and, in turn, increased health 
care expenditure.8–11 Although incorrect inhaler use may be 
due, in part, to a patient’s impaired dexterity (particularly 
with elderly COPD patients), evidence suggests that many 
patients receive inadequate or no training in the use of their 
device.2,8,9,15,16 In a systematic literature review of patients 
evaluated about their use of DPIs for either asthma or COPD, 
one-quarter of the patients had received no verbal instruction 
on inhaler technique.8 For those patients who had received 
instruction, the quality and duration of the instruction and 
review of technique were considered inadequate.8 Perhaps 
more concerning are the findings from several studies that 
many medical and nursing personnel do not have a good 
understanding of correct inhaler technique, despite their 
awareness of the importance of correct technique on treat-
ment outcomes.9,15,17–19 Educational efforts therefore need to 
be focused on primary prescribers of inhaler devices so as to 
limit or avoid the consequences of poor inhaler technique by 
their patients. Written instruction is known to be ineffective 
as a training method; verbal instruction, technique assess-
ment, and reassessment are all essential for achieving correct 
inhaler use.8 Reflecting this need for improved education, 
a call to action for improving education of inhaler technique 
at a policy level was published by the International Primary 
Care Respiratory Group13 and the Aerosol Drug Management 
Improvement Team.15
A meta-analysis of 59 randomized trials assessing 
respiratory treatments delivered by a metered dose inhaler 
(MDI), nebulizer, or DPI has suggested that when inhalers 
are used correctly, there is little difference in clinical efficacy 
between devices.20 Although inhaler selection remains an 
essential component of tailored treatment, the results from 
this meta-analysis highlight that considerable improvements 
in disease management are possible by investing in training 
of correct inhaler use.
Ongoing monitoring of inhaler technique should be an 
integral component of routine management of COPD and 
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Figure 1 Association between asthma and COPD disease control and at least one critical inhaler error.
Notes: (A) Describes the relationship between risk of at least one critical inhaler error and Asthma Control Test questionnaire score. (B) Describes the relationship 
between risk of at least one critical inhaler error and self-reporting of some unscheduled health-care resources use in the last year. Data from Melani et al.57
Abbreviation: COPD, chronic obstructive pulmonary disease.
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asthma patients. An algorithm proposed by the Aerosol 
Drug Management Improvement Team gives prescribers a 
practical tool for assessing whether a change in device type 
is needed or a step-up in therapy is required (Figure 2).2,15 
Although initially developed for asthma patients, this 
algorithm could also be adapted for the management of 
patients with COPD.2
Overview of handheld inhaler 
devices
Handheld inhalers are available as either pressurized MDIs 
(pMDIs), DPIs, or SMI (Respimat®, Boehringer Ingelheim, 
Germany; currently, the only SMI marketed).5 Nebulizers 
are beyond the scope of this review; however, the articles 
by Ibrahim et al21 and Lavorini et al5 provide detailed 
discussions of nebulizer technology. A description of the 
currently available handheld devices is provided, and a 
summary of the advantages and disadvantages of each type 
is given in Table 1.
pMDis
Introduced in the 1950s,22 pMDIs were the first of the 
handheld delivery devices. Technological developments in 
pMDIs have occurred over the past 60 years, but common 
components of all MDIs are a pressurized canister of drug in 
solution or suspension, a chamber for producing an aerosol, 
and a mouthpiece through which the aerosol is inhaled.
Older pMDIs created a high-velocity spray of relatively 
large droplets.23,24 The change in propellants from chlorofluo-
rocarbon to hydrofluoroalkane has led to a reduced-velocity 
spray that delivers a smaller particle size. These properties 
lead to reduced oropharyngeal deposition and improved 
distribution of drug particles throughout the airways with 
newer hydrofluoroalkane pMDIs compared with chlorofluo-
rocarbon MDIs.23–27
In terms of operational design, two generations of pMDI 
device now exist in practice. First-generation pMDIs are 
simple, push-activated, pressure-powered aerosols that 
require precise coordination and inhalation by the patient. 
A valve-holding chamber or spacer with a one-way valve 
allows the aerosol to be inhaled with several intakes and can 
be added to reduce dependency on coordination. Although 
spacers are essential for children and those patients with very 
severe cognitive and physical impairment, they are inconve-
nient to carry and need to be cleaned between uses.16,28
Second-generation pMDIs require breath actuation 
rather than push activation to reduce dependency on the 
patient’s coordination of inhalation and actuation. Currently 
in development is a new generation of “intelligent” pMDIs 
that have electronic computation of delivery to compensate 
for inadequate inhalation and provide more reliable feedback 
on delivery.29
DPis
DPIs rely on air drawn through the device to pick up powder 
from a container and carry it into the lungs within the same 
airstream.24 Some devices require insertion of drug capsules 
designed to release all the powdered content into the airstream. 
Other devices contain multiple doses taken from a reservoir or 
multiple prefilled blisters/cartridges of drug powder.24 These do 
?????????????????????
??????????????
????????? ???????
??????????????????????
????????????????????????????????????
???????????????????
??????
• ???? ???????????
• ?????????????????????
• ?????????????????????
• ????????????β????????????
• ???????????????????????
???
????????????????
??
Figure 2 ADMIT asthma therapy adjustment flow chart.
Note: Adapted from from Respir Med, 100/9, Crompton GK, Barnes PJ, Broeders M, et al, The need to improve inha lation technique in europe: a report from the Aerosol 
Drug Management improvement Team, 1479–1494, Copyright 2006, with permission from elsevier.15
Abbreviation: ADMiT, Aerosol Drug Management improvement Team.
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not require the user to carry packets of separate drug capsules, 
but function is otherwise similar to single-capsule devices.
Inhalation flow rate through the device is critical to the 
successful operation of all DPIs, and the inspiratory effort 
required to deliver the drug to the lungs depends on the 
device. Not all patients are capable of creating sufficiently 
controlled inspiratory effort every time, especially dur-
ing an exacerbation.30 New DPI devices are beginning to 
address this important issue, including the dose protector of 
the NEXThaler® (Chiesi Limited, Manchester, UK), which 
prevents release of the dose until sufficient flow rate is 
achieved,31 and the electronic power-assisted DPIs (active 
DPIs) currently in development.5
Slow-moving SMis
The SMI was introduced in 2007 by Boehringer Ingelheim 
as Respimat® SMI. It comprises design elements from 
the pMDI, but was designed to solve some disadvantages 
Table 1 Major components, advantages, and disadvantages of inhaler devices
Inhaler Formulation Metering system Advantages Disadvantages
pMDi Drug suspended or 
dissolved in propellant 
(with surfactant and 
cosolvent)
Metering valve and 
reservoir
Portable and compact
Multidose device
Relatively inexpensive
Cannot contaminate contents
Available for most inhaled medications
Dose indicator (new-generation devices)
Contains propellants
Not breath actuated
Many patients cannot use it 
correctly
High oropharyngeal deposition
pMDi + spacer Low dependence on inspiratory flow rate
easier to coordinate
Large drug doses delivered more 
conveniently
Less oropharyngeal deposition
Low dependence on inspiratory flow rate
Higher lung deposition than a pMDi
Less portable than a pMDi
Plastic spacers may acquire static 
charge
Additional cost to a pMDi
BA-MDi Drug suspended in 
propellant
Metering valve and 
reservoir
Portable and compact
Multidose device
Breath actuated (no coordination 
needed)
Cannot contaminate contents
Contains propellants
“Cold Freon” effect
Requires moderate inspiratory 
flow to be triggered
DPi Drug blend in lactose, 
drug alone, drug/
excipient particles
Capsules, blisters, 
multidose blister 
packs, reservoirs
Portable and compact
Breath actuated (no coordination 
needed)
Does not contain propellants
Dose indicator (new generation devices)
Locking mechanism when empty  
(new generation devices)
Requires a minimum inspiratory 
flow
May not be appropriate for 
emergency situations
Many patients cannot use it 
correctly
Most types are moisture sensitive
SMi (Respimat®) Aqueous solution  
or suspension
A spring-loaded 
system provides 
the energy required 
to force aqueous 
solution from a 
reservoir through 
the “uniblock” to 
produce the soft 
mist
Portable and compact
Multidose device
Low dependence on inspiratory flow rate 
(slow moving aerosol)
High fine particle fraction
High lung deposition
Does not contain propellants
Dose indicator
Locking mechanism when empty
Not breath actuated
Nebulizers Aqueous solution  
or suspension
Nebule dispensed 
into reservoir 
chamber of 
nebulizer
May be used at any age
No specific inhalation technique required
vibrating mesh is portable and does not 
require an outside energy source
May dispense drugs not available with 
pMDis or DPis
Jet and ultrasonic nebulizers 
require an outside energy source
Treatment times can be long
Performance varies between 
nebulizers
Jet nebulizers cannot aerosolize a 
certain volume of solution
Risk of bacterial contamination
Newer nebulizers are expensive
Note: Data from Lavorini22 and Lavorini et al.5
Abbreviations: BA-MDi, breath-actuated metered dose inhaler; DPi, dry powder inhaler; pMDi, pressurized metered dose inhaler; SMi, Soft Mist™ inhaler.
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associated with pMDIs and DPIs, such as deposition of drug 
in the oropharynx.32 Respimat® uses spring power (rather than 
a pressurized container) to generate a low-velocity vapor 
cloud into the mouth from a liquid formulation of the drug, 
which is pushed through a specially designed nozzle. The 
mist generation is sustained for approximately 1.5 seconds 
but still requires a degree of coordination of inhalation and 
actuation (although less so than for pMDIs).32 Compared 
with pMDI devices, lung deposition with Respimat® is up to 
50% higher and oropharyngeal deposition is lower.5 Typical 
scintigraphic images for Respimat® (Boehringer Ingelheim), 
Turbuhaler® (AstraZeneca, Lund, Sweden) DPI at slow and 
fast inhaled flow rates, and pMDI devices32,33 are shown in 
Figure 3. Respimat® also has the benefit of a dose indicator 
that provides the user with an estimate of doses remaining 
in the cartridge.
inhaler techniques
Each type of device requires a different inhalation technique 
to achieve optimal drug delivery to the lungs (Table 2). 
Furthermore, specific instructions vary between devices. 
This can cause confusion among patients34 and highlights 
why the prescription of multiple inhaler types to one patient, 
or switching to different inhaler types, requires careful man-
agement and discussion with the patient.
Requirements of the “ideal” inhaler
Characteristics of inhaler devices that affect patients’ percep-
tions of their COPD therapy include perceived efficacy, ease 
and convenience of use, how they will feel about using the 
device in public, their physician’s preference, availability 
of the drug or device preparations, loyalty to the brand of 
inhaler, cost, time it takes to learn how to use the device, 
device appearance (size, weight, etc), how to clean the device, 
and disposability/environmental issues.35 The ideal inhaler 
would be small and breath-activated; it would also deliver 
flow-independent drug deposition in the lung and be suit-
able for use in patients who have low inspiratory airflow.36 
It should be lightweight and require no accessories, external 
assistance, or power source to enable its use. In addition, it 
Figure 3 Typical scintigraphic images for Respimat®, Turbuhaler® DPI at slow and fast inhaled flow rates, and pMDI.
Notes: (A) Respimat® SMi; (B) Turbuhaler® DPi – slow; (C) Turbuhaler® DPi – fast; (D) pMDi. Reproduced from Pitcairn G, Reader S, Pavia D, Newman S. Deposition of 
corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med. 
2005;18(3):264–272.33 The publisher for this copyrighted material is Mary Ann Liebert, inc. publishers.
Abbreviations: DPi, dry powder inhaler; pMDi, pressurized metered dose inhaler; SMi, Soft Mist™ inhaler.
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should have the capability to count the number of delivered 
and/or residual doses; not allow degradation of the active 
ingredient; contain no additives, propellants, or excipients; 
and be able to quickly aerosolize the drug.37
The following are some of the factors associated with 
inhaler design and use that can influence how patients interact 
with their inhalers.
Aerosolizing
Conversion of the drug from a compacted to an inhalable form 
requires energy, which is either stored within the device (eg, 
pressurized canister, electronics, or spring) or provided by the 
airflow from the inhalation process. Drug delivery is affected by 
the inspiratory flow rate required to generate drug particles of a 
suitable size for inhalation (eg, 1–5.8 µm) and the fine particle 
fraction of the aerosol (defined as particles 5.8 µm).32,38 These 
factors vary between inhaler devices (Table 1).
Aerosolizing by pMDIs and the SMI is less dependent 
on patient inspiratory effort than for DPIs that require a 
high inspiratory flow rate to ensure correct inhalation and 
deposition of the drug into the lungs.22 This has advantages 
for patients with impaired lung function. However, inspira-
tory flow rates vary between DPIs, depending on the internal 
resistance of the device, eg, the HandiHaler® (Boehringer 
Ingelheim International GmbH) is a flow-limiting device, 
with target flow between 20–30 L/min, compared with 
reported mean flow rates of 82 mL for the Turbuhaler® DPI 
(AstraZeneca) and 117 mL for the Diskhaler® DPI (Glaxo-
SmithKline plc, London, UK; reflecting higher internal 
resistance).39 To produce fine aerosol particles that are 
Table 2 Correct techniques for using pMDI, DPI (specifically HandiHaler®), and SMi (Respimat®) devices
Inhaler type Correct technique Errors in technique
pMDia 1. Shake the inhaler well before use (three or four shakes)
2. Remove the cap
3. Breathe out, away from inhaler
4. Place inhaler between teeth and close mouth around it
5. Start to breathe in slowly. Press the top of inhaler once and 
keep breathing in slowly until a full breath has been taken
6. Remove the inhaler and hold breath for about 10 seconds, then 
breathe out
7. if a second puff is needed, wait 30 seconds, shake inhaler again, 
and repeat above steps
8. Rinse mouth (after iCS) and record the number of doses taken
inhaler not primed
inhaler not shaken
No exhalation
Holding mouthpiece away from mouth/poor seal 
around mouthpiece
Firing device before start of inhalation
Firing device at or after end of inhalation
inhaling through nose
Stopping inhalation as device is fired
Fast inhalation
No breath-hold/short breath-hold
HandiHaler® (DPi)b,c 1. Open the HandiHaler® device. Separate only one of the blisters 
from the blister card; then open the blister
2. insert the Spiriva® (Boehringer ingelheim) capsule and close the 
mouthpiece firmly against the gray base until a click is heard
3. Press the green piercing button once until it is flat (flush) 
against the base, then release
4. Breathe out completely. Then, with the HandiHaler® in the 
mouth, breathe in deeply until lungs are full. Patient should hear 
or feel the Spiriva® capsule vibrate (rattle)
5. Patient must inhale twice from the same Spiriva® capsule in 
order to take full daily dose
incorrect dose loading
Failure to pierce capsule or release piercing button
Breathing out into device
inhalation vents blocked
Poor seal around mouthpiece
Patients inhaling too forcefully (40–50 L/min)d
Insufficient flow “acceleration”
inhaling through nose
No breath-hold/short breath-hold
inappropriate storage
Respimat® (SMi)e,f 1. Keep cap closed. Turn base in direction of the arrows on label 
until a click is heard
2. Flip cap open until it clicks into open position
3. Close lips around the mouthpiece end. while taking in a slow, 
deep breath, press dose release button; keep breathing in 
slowly. Close cap
4. Repeat for a total of two puffs
Failure to prime device/load dose
Failure to open mouthpiece cap
No exhalation
Mouthpiece vents blocked
Firing device before start of inhalation
Firing device at or after end of inhalation
inhaling through nose
Stopping inhalation as device is fired
Fast inhalation
No breath-hold/short breath-hold
Notes: ainstruction manual (Canada); binstruction manual (USA); cHandiHaler® SmPC;58 dCrucial error for some DPis; einstruction manual (USA); fRespimat® SmPC.59 Data 
from Newman.60,61
Abbreviations: DPi, dry powder inhaler; iCS, inhaled corticosteroids; pMDi, pressurized metered dose inhaler; SMi, Soft Mist™ inhaler; SmPC, summary of product 
characteristics.
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inhalable and maximize drug deposition in the lung,32,38 the 
target minimum inspiratory flow rates are 50 L/min for a 
high-resistance DPI, compared with 50–60 mL for a medium-
resistance DPI and 90 L/min for a low-resistance DPI.5
Inhaler design also affects the extent to which the aerosol 
contains fine particles. A high fine particle fraction allows 
more of the drug dose to be deposited in the lung, rather than 
in the oropharynx.32 It has been shown that the fine particle 
fraction of the aerosol generated using the SMI is approxi-
mately 75%, which is more than twice the value reported for 
pMDIs or DPIs.38 However, other new generation inhalers, 
such as the NEXThaler® DPI (Chiesi Limited), have evolved 
to deliver extrafine drug particles that can increase drug 
deposition throughout the bronchial tree.5,40
All methods of aerosolizing require the use of carriers 
and excipients, whether they are gaseous, liquid, or solid. 
Although they are pharmacologically inert, they can pro-
duce a cold sensation that may cause the patient to stop 
inhaling.24 SMIs do not require propellants,41 and excipients 
are minimized. The delivery of the drug as a mist aerosol 
avoids the cool sensation from evaporating gases that can 
be experienced with pMDIs.16 This may be beneficial for 
some patients.
Delivery
After the patient aerosolizes the drug into their mouth, their 
inhalation flow must carry the aerosolized drug into the 
lungs – a process highly influenced by the patient. Failure of 
the drug to be effectively delivered into the lungs can result 
in a diminished dose as well as the potential for local side 
effects (eg, sore throat) from oropharyngeal deposition of the 
drug.42,43 In addition, drug deposited in the oropharynx may 
be swallowed, leading to gastrointestinal absorption, which 
may contribute to systemic side effects. Ideally, drug reaching 
the lungs is targeted to the airways, where bronchodilatory 
and/or anti-inflammatory effects will provide the greatest 
benefit, with minimal alveolar deposition, since this is the 
main site of systemic absorption in the lungs.44
Advancements in inhaler design have greatly improved 
drug delivery and have allowed lower nominal doses of drug 
to be used to achieve control in asthma and COPD, thus 
minimizing the risk of overdosing.33 For example, the SMI 
Respimat® delivers a slow-moving spray cloud that is of a 
longer duration and smaller droplet size than the spray from 
a pMDI, which results in deposition of a higher proportion 
of the drug in the lungs compared with pMDIs and some 
DPIs.33
Dependability
Frequent cleaning of devices is often necessary16 since the 
drug can be deposited on the device and accumulation is 
inevitable. Nozzles can easily become blocked without regu-
lar maintenance. Microbial contamination is also possible 
within inhalers and spacer devices.45,46 Cleaning regimens 
must be as simple as possible to encourage compliance 
with this important component of inhaler use and to ensure 
operational reliability of the device.
Perceived efficacy of an inhaler is an important factor 
influencing patients’ device preferences.35 Reassurance from 
device feedback interfaces such as dose counters has been 
shown to be important in improving treatment adherence, 
reminding patients when to replace cartridges, and preventing 
patients from using their inhalers beyond the recommended 
number of doses.5,11
Matching inhalers to the patient’s 
physical ability
The authors of this review and others have previously pro-
posed an algorithm for the selection of a particular inhaler 
device based on the patient’s physical abilities (Figure 4).12 
The algorithm considers three questions: 1) Is the patient 
capable of conscious inhalation? 2) Is the patient likely to 
reliably generate and control sufficient inspiratory flow? 
3) Is the patient capable of hand–inhalation coordination?
Using this algorithm, patients evaluated as having sufficient 
inspiratory flow with good coordination would be suited to a 
pMDI (with or without spacer), DPI, or SMI (ie, Respimat®, 
Boehringer Ingelheim); those with poor coordination may 
require a breath-actuated pMDI with spacer, DPI, or SMI.12 
For patients with insufficient inspiratory flow but adequate 
coordination (eg, patients with severe COPD or asthma and 
recurrent exacerbations), a pMDI (with or without spacer) or 
SMI would be suitable.12 Options for patients with both insuf-
ficient inspiratory flow and poor inhaler coordination include 
a breath-actuated pMDI (with spacer), SMI, or nebulizer.12 
According to the algorithm, the attributes of the SMI make it an 
appropriate choice for all patients who are capable of conscious 
inhalation, irrespective of their hand–inhalation coordination 
or ability to generate sufficient inspiratory flow.
Components of patient preference 
and satisfaction with inhalers
As with all treatment decisions, it is important that the patient 
be involved in the choice of inhaler device. Patients are more 
likely to use a device effectively if they are comfortable with 
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it and can use it even when they are incapable of achieving 
high inspiratory flow rates.30
Many studies have investigated patients’ preferences 
for different inhaler types.31,35,41,47–50 While acknowledging 
that many preference studies are sponsored by the device 
or respiratory drug companies, such studies can provide 
valuable insights into the features that patients consider to 
be most important in a device. These include simplicity and 
convenience (eg, size, durability), and experience of use 
(eg, taste, side effects).9,35
Simplicity and convenience
Ease of use is an important factor in adherence with any 
device, but it is particularly important with drug delivery 
devices for maintenance treatment.5 Use of electronics and 
other automations can reduce dependency on the patient for 
accurate technique, but it adds to the cost and complexity in 
terms of potential faults and possible cleaning issues.
In several surveys of device preference, ease of use 
has been ranked by patients as one of the most important 
features;47,48,51,52 however, perception of ease of use varies 
among patients. Patient perception of the level of conve-
nience that is offered by the device might take into account 
its size, the instructions for use, its durability, the ease of 
cleaning the device, how comfortable it is to use (eg, for 
arthritic hands), and its portability.48
Patients want procedures to be as simple as possible, and 
one study found that 18% of patients stopped inhaled therapy 
spontaneously due to perceived complexity.53 Complexity 
and confusion between required techniques may ensue when 
mixed types of inhaler devices are prescribed for the delivery 
of different drug therapies.34
experience
Overall experience with an inhaler may be influenced by aspects 
unrelated to its physical form or functionality. Side effects from 
the drug, excipient, or inhaler use can affect the patient’s expe-
rience and willingness to continue using the device. Common 
issues with inhalers are the presence of an aftertaste, an effect 
on the throat (such as cold, dry, or sore), and cough.
Poor delivery and/or slow onset of action can reinforce 
a patient’s decision to voluntarily discontinue their regular 
medication. Indeed, lack of perceived benefit has been 
reported to account for 30% of patients with COPD inten-
tionally discontinuing their therapy.11
Apprehension regarding switching device
Patients may be apprehensive when switching to a new 
inhaler device because they may need to learn new skills and 
put these into practice with only limited training.16
experience with SMi versus other inhaler 
types
A number of studies comparing the patients’ experience of 
using SMI with other inhaler devices illustrate the influence 
of some of the factors already described in this section.
Figure 4 Algorithm for choosing inhaler device according to the patient’s inspiratory flow and ability to coordinate inhaler actuation and inspiration.
Note: Reprinted from Respir Med, 107/12, Dekhuijzen PN, vincken w, virchow JC, et al, Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective 
approach, 1817–1821, Copyright 2013, with permission from elsevier.12
Abbreviations: BA-pMDi, breath-actuated pressurized metered dose inhaler; DPi, dry powder inhaler; pMDi, pressurized metered dose inhaler; SMi, Soft Mist™ inhaler.
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Hodder and Price35 have reviewed patient preference 
studies of Respimat®. The device was shown to be consis-
tently well accepted and preferred by patients with COPD 
and asthma, with almost three-quarters of patients express-
ing a preference for Respimat® over a pMDI or Turbuhaler® 
DPI (AstraZeneca; Figure 5).35 In another trial of device 
switching in patients with COPD, 21 of 29 patients (72%) 
considered Respimat® to be easier to use than HandiHaler®; 
no patient thought HandiHaler® was easier to use than 
Respimat®.41
Features relating to ease of handling (irrespective of 
patient age) are commonly reported as reasons for patients 
preferring Respimat® over other devices.35 In the two afore-
mentioned studies in which patients rated their satisfaction 
with Respimat® compared with a pMDI or Turbuhaler® DPI, 
Respimat® consistently scored significantly higher on ease of 
handling during use. Durability of the device and numerous 
aspects of device performance were also rated better with 
Respimat® than with pMDI or Turbuhaler®. Size was the only 
parameter on which Respimat® scored significantly worse 
than pMDI or Turbuhaler® in these studies; however, ease 
of carrying the device was not rated significantly worse, and 
there was no negative impact of size on ease of handling, 
which, as noted above, was rated higher for Respimat® in 
both studies.48,54
One survey of patients with COPD suggested that 
Respimat® had a significantly milder aftertaste than 
HandiHaler®, but there were no significant differences 
between the incidence of surveyed adverse events, including 
dry mouth and throat-related side effects.55 In another survey, 
Respimat® was associated with increased incidence of cough 
within the first 4 weeks of switching from HandiHaler®; how-
ever, this was transient and most patients overcame having 
a cough as they got used to using Respimat®.41
Satisfaction with performance of tiotropium Respimat®, 
including feeling of inhalation and reliable working of 
the inhaler, was shown in a patient preference study to 
be consistently better than that of a DPI (Turbuhaler®, 
AstraZeneca).48
In a survey of patients with COPD that evaluated their 
handling experiences and preferences 8 weeks after switching 
from tiotropium HandiHaler® to Respimat®, 46% of patients 
stated that they preferred Respimat®.55 In a follow-up study, 
2–3 years later, the proportion of patients who expressed 
a preference for Respimat® had significantly increased to 
80% (P0.0001).55 The different responses obtained during 
the first and second surveys may suggest that the change in 
inhaler device was stressful for the patients. This highlights 
the importance of involving patients in their treatment deci-
sions to ensure that they are comfortable with, and understand 
the need for, any change in treatment.
Identifying the noncompliant 
patient
Improved compliance and adherence to therapy is a quest 
that is common to many chronic conditions. It is particularly 
important among patients with COPD in order to slow disease 
progression, maintain quality of life, and reduce mortality. 
Tools such as patient questionnaires and decision algorithms 
that can be easily adapted and implemented within daily 
practice may help physicians to select the devices most suited 
to their patients’ needs and abilities; they may also help to 
Figure 5 Proportions of patients indicating preference for Respimat® SMi versus alternative inhaler devices in three studies using the Patient Satisfaction and Preference 
Questionnaire.
Notes: Respimat® SMi versus (A) pMDi, (B) Turbuhaler®, (C) Diskus®. Republished with permission of Dove Medical Press, from Patient preferences for inhaler devices 
in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler, Hodder R, Price D, Int J Chron Obstruct Pulmon Dis, 4, copyright 2012;35 permission 
conveyed through Copyright Clearance Center, inc.
Abbreviations: pMDi, pressurized metered dose inhaler; SMi, Soft Mist™ inhaler.
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identify patients who have the potential for poor compliance 
or incorrect inhalation technique.
Involving the patient in their treatment decision-making 
process can change the physician–patient relationship from 
one of noncompliance to one of participative adherence to 
treatment.47 But how can clinicians identify patients who are 
likely to be noncompliant with their inhaler therapy?
Identification of patients most likely to be noncompliant 
with therapy may enable more effective targeting of educa-
tional and behavioral resources, including continued assess-
ment of inhaler technique, to foster improved compliance 
and maximize treatment efficacy. Sanduzzi et al11 evaluated 
several methods that can assess whether a patient will be 
compliant with their prescribed inhaler; they proposed that 
simple, brief questionnaires based on the Morisky scale56 
were most effective (Table 3).11 These questionnaires address 
patients’ attitudes toward their medications and their health, 
the regularity of their medical check-ups, and their home 
life situation.11 Similar preference questionnaires could be 
refined for ease of use in consultation rooms to gain a better 
understanding of individual patient preference and prescrib-
ing needs.
Conclusion
This review highlights the importance of understanding 
patient capabilities and preferences, and matching these to the 
most appropriate type of inhaler device; it also stresses the 
need to adopt ongoing training and monitoring of inhaler 
technique. With the large array of devices currently available 
to the prescribing physician, it is increasingly important to 
understand the factors that influence a patient’s preference 
and the likelihood of the inhaler being used correctly (eg, ease 
of use and convenience). Respimat® represents a novel class 
of inhaler (SMI) that overcomes some of the drawbacks 
associated with pMDIs and DPIs, such as nontargeted 
deposition of drug. It might be expected that SMIs in devel-
opment will perform in a similar maner to Respimat® with 
regards to what benefits patients.
Patient satisfaction and preference studies have consis-
tently shown Respimat® to be well accepted by patients, 
with higher levels of satisfaction and preference versus 
HandiHaler® and other device types. Whether the observed 
preference for Respimat® ultimately translates into improved 
adherence to therapy and improved outcomes remains to be 
evaluated in clinical studies.
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Table 3 Proposed psychosocioeconomic questions to ask patients with COPD to estimate compliance and to assess adherence 
phenotype and status
Questions for a treatment naïve patient prior to prescribing 
inhaled therapy
Questions for patients already under treatment to confirm 
adherence to inhaled therapy
How many different medications do you take every day?
who do you live with?
Are you worried?a
would you stop taking a medication if it gave you side effects  
or if it was too complicated to take?
what do you think about inhaled medications?
Do you see any pulmonologists for check-up examinations?
How often did you forget to take your inhaled therapy in the past month?
Are you more likely to forget taking your medicines in the morning or the 
evening?
Do you find your therapy dangerous?
Do you prefer inhaled drugs to oral tablets?
Do you think your prescription is appropriate for your disease?
Notes: Each question has a defined set of four responses. Responses are scored using the Morisky scale to give a general indicator of risk.11 See Sanduzzi et al11 for the 
complete questionnaires. aQuestion relates to the patient’s health condition, and economic and family situations. Data from Sanduzzi et al.11
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